Skip to main content

Advertisement

SpringerLink
Log in

The role of lipids and uremic toxins in cardiovascular disease in CKD

  • Review Article
  • WCN 2013 Satellite Symposium ‘‘Kidney and Lipids’’
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Lipid abnormalities and uremic toxins are features of chronic kidney disease (CKD) and may influence cardiovascular outcomes in CKD patients. Recent data suggest that uremic toxins may modulate lipoprotein levels and composition (e.g., oxidation or carbamylation) and enhance the cardiovascular toxicity of lipoproteins in CKD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Massy ZA, de Zeeuw D. LDL cholesterol in CKD-to treat or not to treat? Kidney Int. 2013 (May 22 on line).

  2. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W, European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934–43.

    Article  CAS  PubMed  Google Scholar 

  3. Massy ZA, Stenvinkel P, Drueke TB. The role of oxidative stress in chronic kidney disease. Semin Dial. 2009;22:405–8.

    Article  PubMed  Google Scholar 

  4. Apostolov EO, Basnakian AG, Ok E, Shah SV. Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic kidney disease. J Ren Nutr. 2012;22(1):134–8.

    Article  CAS  PubMed  Google Scholar 

  5. Apostolov EO, Ray D, Savenka AV, Shah SV, Basnakian AG. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol. 2010;21(11):1852–7.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Koppe L, Pillon NJ, Vella RE, Croze ML, Pelletier CC, Chambert S, Massy Z, Glorieux G, Vanholder R, Dugenet Y, Soula HA, Fouque D. Soulage CO p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol. 2013;24(1):88–99.

    Article  CAS  PubMed  Google Scholar 

  7. D’Apolito M, Du X, Zong H, Catucci A, Maiuri L, Trivisano T, Pettoello-Mantovani M, Campanozzi A, Raia V, Pessin JE, Brownlee M, Giardino I. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Invest. 2010;120(1):203–13.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Trécherel E, Godin C, Louandre C, Benchitrit J, Poirot S, Mazière JC, Massy ZA, Galmiche A. Upregulation of BAD, a pro-apoptotic protein of the BCL2 family, in vascular smooth muscle cells exposed to uremic conditions. Biochem Biophys Res Commun. 2012;417(1):479–83.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Nephrology, Ambroise Paré Hospital, Paris Ile de France Ouest University (UVSQ), 09 Avenue Charles de Gaulle, Boulogne Billancourt, 92100, Paris, France

    Ziad A. Massy

  2. INSERM U-1088, UPJV, Amiens, France

    Ziad A. Massy

Authors
  1. Ziad A. Massy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ziad A. Massy.

About this article

Cite this article

Massy, Z.A. The role of lipids and uremic toxins in cardiovascular disease in CKD. Clin Exp Nephrol 18, 255–256 (2014). https://doi.org/10.1007/s10157-013-0864-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-013-0864-y

Keywords

Search

Navigation